Woman, 24, diagnosed with life-changing condition after collapsing in gym
Harriet Davidson was diagnosed with lymphangioleiomyomatosis (LAM) in 2019 after suffering a collapsed lung while at the gym - she was told her lung function will decline rapidly
A woman diagnosed with a rare and incurable lung disease at the tender age of 24 is seizing the day despite her challenging condition. Harriet Davidson smashed expectations last weekend by completing the 10km course at the Great Bristol Run, an achievement that seemed out of reach a few years back when she had to endure major lung surgery.
Back in April 2019, Harriet was struck by a sudden lung collapse while working out at the gym, with no apparent cause. After a fortnight in hospital, it wasn't until a CT scan that doctors spotted hundreds of cysts on her lungs.
She was then diagnosed with lymphangioleiomyomatosis (LAM), a rare condition that targets the lungs and kidneys and mainly affects women. Now at 30, she's spent months training to finish the 10km race, all the while raising awareness and funds for the charity that's been her rock during her health ordeal.
Harriet, from Bristol, said: "This disease has truly changed my life. I was told my lung function will decline rapidly, and that I may have a short life and might even require a lung transplant. Fast forward six years, I have had the best fitness I may have ever had.
"I have been training so hard for the Bristol 10km, taking up running, something I thought I would never enjoy. Playing football again, cycling, and living life to the full."
While battling her own health struggles, Harriet has stepped up as a key advocate for those dealing with LAM. She heaps praise on the charity LAM Action for giving her access to Rapamycin, a medication she believes could be life-saving.
Gaining international attention, she even took to the stage in Chicago to shine a light on the illness, reports Bristol Live. Harriet didn't know about her condition when she was treated for a benign kidney tumour back in 2013; it's a rare disease, impacting roughly 350 women across the UK.
With a finishing time of 1:05:08, Harriet has drummed up over £6,000 for LAM Action. Alongside her at the starting line were about 50 mates, loved ones, and well-wishers who gathered on Sunday, May 11.
This event meant the world to Harriet not just due to her health saga but also as it represented the biggest turnout for LAM Action yet, all sporting branded T-shirts to champion the cause.
Harriet expressed her heartfelt gratitude: "Without their support, I would never have been offered the medication Rapamycin, which could potentially save my life.
"I will forever be grateful for the contributions of scientists, clinicians and charities who have allowed me to be in the position that I am now."
Dedicated to aiding women and families grappling with the condition, LAM Action pushes for improved treatment options and rigorous research.
Harriet expressed her commitment, saying: "I endeavour to support other women like me, especially for those who haven't been as lucky as me, who have to have a lung transplant, and their families, and to provide the continued support for patients coming to terms with an incurable disease."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
3 days ago
- Daily Mirror
'Worst ever' drug shortage leaves cancer patients unable to eat
Shortages of Creon, which replaces a key enzyme needed to digest food, means patients with pancreatic cancer, cystic fibrosis and chronic pancreatitis are rationing meals Thousands of cancer and cystic fibrosis patients are being hit by a critical shortage of a key drug they need to help them digest food. Pharmacists are warning some patients are only eating once a day to ration supplies of the drug Creon. Patients with chronic pancreatitis are also among around 60,000 people who rely on the drug which replaces a key enzyme in what one pharmacist called the "worst stock shortage" they have ever had to deal with. The National Pharmacy Association surveyed 300 pharmacies and found 96% were having trouble supplying Creon, which is subject to the Government's serious shortage protocols (SSP). Creon is a pancreatic enzyme replacement therapy (Pert) which helps people digest food and absorb its nutrients. A Europe-wide problem in getting hold of stocks is being caused by a shortage of its raw ingredients. Patients like Harriet Corr, 9, from Hebburn, Tyneside, who suffers from Cystic fibrosis are being advised to basically cut back on their calories to reduce the amount of Creon tablets they need. People with CF struggle as it is to keep weight on so this can be dangerous. Speaking last year, her mum Emma Corr told the Express: Emma, of Hebburn, Tyne and Wear, told the Daily Express: "Harriet needs about 10-15 Creon tablets every day and usually it's never a problem getting any. But people increasingly seen unable to source Creon anywhere. It's becoming a full blown crisis. We're now unable to find it either. "We've been scouring our house to see if we've left any pots of Creon lying about - that's how desperate we're getting. Not only does Creon help Harriet absorb the nutrients and fats in her food but it enables her CF drug Kaftrio to work properly too. If we have to reduce the fats in her diet not only will she lose weight but it could mean her Kaftrio does not fully work either." The NPA survey heard examples of patients in distress such as those eating one meal a day to ration their Creon, going without medication or travelling long distances and contacting numerous pharmacies in an attempt to find stock. The NPA said some are travelling more than 30 miles to get hold of a pack of the drug. Some 89% of pharmacies also reported difficulties in supplying Pert alternatives. Olivier Picard, chairman of the NPA, said: "Pharmacies are at the sharp end of medicine shortages, spending hours hunting stock and supporting frustrated and concerned patients. "As this distressing survey shows ongoing supply problems with Creon has had a profound effect on the patients who depend on it to survive and lead a normal life. It simply cannot be right that in the 21st century patients are skipping meals in order to ration their medication.' Alfie Bailey-Bearfield, head of influencing and health improvement at Pancreatic Cancer UK, said: "These deeply worrying findings echo the distress and frustration we are hearing from patients and their loved ones across the UK. "Thousands of people affected by pancreatic cancer rely on taking Pert tablets every time they eat simply to digest their food and absorb nutrients - something most of us take for granted. It's totally unacceptable that they are still taking desperate measures which puts their health, wellbeing and their eligibility for treatment at risk.' The Government has extended the current serious shortage protocols (SSP) in place for Creon until November. This allows pharmacists to supply a reduced quantity of Creon capsules that might be in stock, without having to send a patient back to their GP for a new prescription. The NPA survey also found that 81% of pharmacies felt the current arrangements for managing shortages of Creon were inadequate. It found pharmacists are still having to refer patients back for new prescriptions for an alternative Pert product, stock permitting, or an unlicensed Creon product. Olivier Picard, of the NPA, added: "Although we recognise this situation is complex and not the fault of the Government, it's important they convene a taskforce and a national action plan to tackle this particular shortage given its impact on patients. "Medicine shortages are all too common so highly trained pharmacists should also be permitted to use their professional judgment to supply alternative medicines - where it is safe and appropriate - in the event of the prescribed version being unavailable." Alfie Bailey-Bearfield, of Pancreatic Cancer UK, added: "For over a year, we have been raising concerns with Department of Health and Social Care officials and Pert suppliers, urging them to prioritise solutions that reduce the impact on patients. But despite these conversations, progress has been far too slow and patients continue to pay the price. "It is critical that they take immediate, decisive action and explore every available option to increase supply, including directly purchasing this vital medication from countries with a surplus. This crisis continues to put people's health on the line, and they cannot afford to wait any longer. The situation is unacceptable and it demands immediate action." A Department of Health and Social Care spokesman said: "We know how frustrating and distressing medicine supply issues can be for patients and the clinicians caring for them. "The European-wide supply issues with Creon are caused by a limited availability of raw ingredients and manufacturing capacity constraints. We are working closely with industry and the NHS to mitigate the impact on patients and resolve the issues as quickly as possible."
Daily Mirror
6 days ago
- Daily Mirror
GMB star called 111 over bowel cancer fears ahead of emergency surgery
Good Morning Britain star Ranvir Singh has returned to the ITV daytime show following her emergency appendix surgery. Good Morning Britain's Ranvir Singh has opened up about her recent health scare and emergency surgery on Friday's episode of the show. While chatting with Made in Chelsea's Sam Vanderpump, who recently faced a life-threatening battle with liver and kidney failure leading to sepsis, Ranvir shared her own brush with a medical emergency. The 27-year-old reality star emphasised the importance of seeking medical advice for sepsis symptoms, prompting Ranvir to recount her experience when her appendix ruptured just weeks ago. Ranvir recalled the moment she decided to call 111 after enduring pain all day post-work, saying: "It's interesting, you know when I had my appendix ruptured a couple of weeks ago, about three weeks ago, the thing that made me call 111, I had sort of been writhing around all day straight after work." She linked her decision to Lorraine's team raising awareness about bowel cancer, stating: "It was eight o'clock at night, and I thought, 'Let's check it's not bowel cancer'. I don't know, it's because Lorraine's team have been doing a bowel cancer thing." Highlighting the impact of health campaigns, she added: "So, raising awareness genuinely works in the moment when you're in pain, you go, 'What could it be?'. So just planting a seed in the mind of someone." Co-host Rob Rinder then chimed in, revealing that initially, doctors dismissed Ranvir's severe pain, asking: "They told you it was nothing, I think, at first?" to which Ranvir confirmed: "Yeah." Earlier in May, Ranvir took to Instagram to tell her followers that she had to undergo urgent surgery after her appendix burst, despite having presented Lorraine just the day before, reports Bristol Live. After feeling drained and foggy and thinking a coffee could sort it, TV star Ranvir Singh was struck by a sudden stomach ache. She shared her ordeal on social media, saying: "I stay in bed all day. Turns out I had a ruptured appendix and had urgent surgery at midnight on Thursday! "Woke up 5am on Friday morning, high on anaesthetic and certain I could get into work to host the show as normal [laughing emoji]. "Pretty nasty few days, the bacteria had spread and infected my blood etc and told to take this week off by @jadeens I'm sore and shuffling around, can't drive for a week, and no exercise for 4 weeks (! ) so really it's the boredom that will kill me!" With 'horrendous' shoulder pain also afflicting her, well-wishers flooded in with supportive messages for Ranvir. Despite the health scare, the resilient presenter returned to hosting duties on ITV alongside Rob Rinder on Friday.
The Independent
29-05-2025
- The Independent
Drug combination found to extend lifespan by 30 per cent
A combination of two cancer drugs significantly boosts lifespan in mice, according to a new study that may lead to better strategies for longevity. The drugs rapamycin and trametinib given together as a combination can increase mice lifespan by up to 30 per cent, say researchers, including from the Max Planck Institute for Biology of Ageing. Trametinib alone can extend lifespan by 5 to 10 per cent and rapamycin by 15–20 per cent, according to the study published in the journal Nature Ageing. Researchers say the drug combination has several other positive effects on mice health in old age, including less chronic inflammation in tissues and a delayed onset of cancer. Previous studies showed potent anti-ageing effects of rapamycin in several animals. Trametinib wasn't known to extend lifespan in mice but previous research in flies indicated it might. In humans, the two drugs have been used for cancer treatment. While both drugs act on the same chemical network in the body, their combination appears to achieve novel effects that are likely not attributable to just an increase in dosage. Gene activity analysis of mice tissues shows the combination influences genes differently than is achieved by administering the drugs individually. The analysis reveals specific gene activity changes that are only caused by the combination of the two drugs. In further studies, researchers hope to determine the optimal dose and route of administration of trametinib to maximise its life-prolonging effects while minimising unwanted side effects. 'Trametinib, especially in combination with rapamycin, is a good candidate to be tested in clinical trials as a geroprotector,' Sebastian Grönke, a co-author of the study, says. 'We hope that our results will be taken up by others and tested in humans. Our focus is on optimising the use of trametinib in animal models.' While the exact same kind of effect may not be possible in humans, researchers hope the drugs can help people stay healthy and disease-free for longer in life. "Further research in humans in years to come will help us to elucidate how these drugs may be useful to people and who might be able to benefit,' British geneticist Dame Linda Partridge said in a statement. Scientists hope the drug combination may be developed into a promising strategy for combating age-related diseases and promoting longevity.
